A novel marker ADAM17 for clear cell renal cell carcinomas: Implication for patients’ prognosis
- 1 November 2014
- journal article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 32 (8) , 1272-1276
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Outcomes and Clinicopathologic Variables Associated With Late Recurrence After Nephrectomy for Localized Renal Cell CarcinomaUrology, 2011
- Reassessing the Current UICC/AJCC TNM Staging for Renal Cell CarcinomaEuropean Urology, 2009
- ADAM17 upregulation in human renal disease: a role in modulating TGF-α availability?American Journal of Physiology-Renal Physiology, 2009
- Role of ADAMs in Cancer Formation and ProgressionClinical Cancer Research, 2009
- Targeting TACE-dependent EGFR ligand shedding in breast cancerJournal of Clinical Investigation, 2007
- Multiple Acquired Renal Carcinoma Tumor Capabilities Abolished upon Silencing of ADAM17Cancer Research, 2006
- ADAMs, cell migration and cancerCancer and Metastasis Reviews, 2006
- Role of molecular markers in the diagnosis and therapy of renal cell carcinomaUrology, 2005
- TACE is required for the activation of the EGFR by TGF‐α in tumorsThe EMBO Journal, 2003
- Prognostic significance of morphologic parameters in renal cell carcinomaAmerican Journal of Surgical Pathology, 1982